Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 | P11229 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.46 |
| ▸ | HSD11B1 | P28845 | 6/20 | 0.46 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3478043 | 1.00 | CHRM1 (0.47) | CHRM1KDM4EHSD11B1PIK3CDMEN1 | |
| SCHEMBL8211157 | 1.00 | CHRM1 (0.47) | CHRM1KDM4EHSD11B1PIK3CDMEN1 | |
| SCHEMBL15451848 | 0.93 | CHRM1 (0.52) | CHRM1KDM4EHSD11B1PIK3CDMEN1 | |
| SCHEMBL12141187 | 0.85 | CHRM1 (0.49) | CHRM1KDM4EHSD11B1PIK3CDMEN1 | |
| SCHEMBL13324885 | 0.84 | MEN1 (0.41) | PIK3CDMEN1KMT2AALDH1A1 | |
| SCHEMBL12767377 | 0.84 | CYP2C19 (0.45) | KDM4EPIK3CDALDH1A1CYP2C19 | |
| SCHEMBL3419604 | 0.82 | PIK3CD (0.66) | KDM4EPIK3CDALDH1A1CYP2C19 | |
| SCHEMBL12726889 | 0.82 | PIK3CD (0.66) | KDM4EPIK3CDALDH1A1CYP2C19 | |
| SCHEMBL21730496 | 0.82 | EPHX2 (0.47) | CHRM1KDM4EHSD11B1PIK3CDMEN1 | |
| SCHEMBL12726865 | 0.82 | PIK3CD (0.66) | KDM4EPIK3CDALDH1A1CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8993563-B2 | Phosphoinositide 3-kinase inhibitor compounds and methods of use | GENENTECH, INC. (US) | 2015-03-31 | — | — | US | disclosed |
| US-20130129820-A1 | PHOSPHOINOSITIDE 3-KINASE INHIBITOR COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2013-05-23 | — | — | US | disclosed |
| EP-2518074-A1 | Phosphoinositide 3-kinase inhibitor compounds and methods of use | F. Hoffmann-La Roche AG (CH) | 2012-10-31 | — | — | EP | disclosed |
| WO-2008070740-A1 | PHOSPHOINOSITIDE 3-KINASE INHIBITOR COMPOUNDS AND METHODS OF USE | F.HOFFMANN-LA ROCHE AG (CH) | 2008-06-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130129820-A1 | PHOSPHOINOSITIDE 3-KINASE INHIBITOR COMPOUNDS AND METHODS OF USE | PIK3CA, AKT3, PI4KA | CHRM1 2270/4885KDM4E 3769/4885HSD11B1 1208/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.